We are interested in expanding our approach against other pathogens and in examining evolutionary mechanisms. There are several interesting questions to ask.
- Some of our guide peptides are targeted against virulence factors. If resistance arises against these guided antimicrobial peptides, will the resulting pathogen population be avirulent (have mutated virulence factors)?
- Would the evolution of resistance cease if a cocktail of guided antimicrobial peptides were used, each with a guide targeting a different pathogen protein?
- Is the long-term effect of our technology on the microbiota so mild that these probiotics could be used as prophylactic drugs?